Mechanism of Action
Hypothalamic Satiety Signaling
Nesfatin-1 is expressed in hypothalamic nuclei including the paraventricular nucleus (PVN), supraoptic nucleus (SON), and arcuate nucleus. It activates alpha-msh/" class="wiki-internal-link">melanocortin 3/4 receptors (MC3R/MC4R) via a leptin-independent pathway, reducing food intake and body weight. Central administration (ICV) potently suppresses feeding even in leptin-deficient ob/ob mice.
Peripheral Actions
Beyond the hypothalamus, nesfatin-1 is expressed in the stomach (X/A-like cells), pancreatic beta cells, heart, and testes. It inhibits gastric acid secretion, modulates insulin secretion, and exerts anti-inflammatory effects in peripheral tissues. Circulating nesfatin-1 levels are reduced in obesity and type 2 diabetes.
Research Summary
Obesity and Appetite
PreclinicalRodent studies show that ICV or IP nesfatin-1 reduces food intake by 20-40% and promotes weight loss over days of administration. Chronic subcutaneous infusion in diet-induced obese mice reduces adiposity without inducing resistance, a key distinction from leptin.
Metabolic Effects
PreclinicalNesfatin-1 improves glucose tolerance and insulin sensitivity in rodent models of type 2 diabetes. Pancreatic nesfatin-1 appears to potentiate glucose-stimulated insulin secretion. These dual central-peripheral metabolic actions suggest therapeutic potential for metabolic syndrome.
Stress and Anxiety
PreclinicalNesfatin-1 neurons overlap substantially with stress-responsive circuits. Central administration activates the HPA axis and increases anxiety-like behavior in rodents. This stress-appetite coupling may be relevant to stress-induced anorexia.
Calculate your Nesfatin-1 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Appetite suppression (rodent) | 1-10 pmol/kg ICV | Single injection | Intracerebroventricular |
| Glucose tolerance (rodent) | 10-50 ug/kg IP | Daily | Intraperitoneal |
| Plasma level assessment | N/A | N/A | Blood draw (ELISA) |
No human clinical trials. All protocols are rodent research contexts. Human therapeutic application is speculative.
Interactions
Safety Profile
No human safety data exists. In rodent studies, ICV nesfatin-1 causes anxiety-like behavior at higher doses and activates the HPA stress axis. Peripheral administration appears better tolerated. No commercial human-grade product exists; nesfatin-1 is a research-only compound with no established human dosing framework.
References
- [1]Oh-I S, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709-712.
- [2]Shimizu H, et al. Nesfatin-1: an overview and future clinical application. Endocr J. 2009;56(4):537-543.
- [3]Stengel A, Tache Y. Nesfatin-1, role as possible new potent regulator of food intake. Regul Pept. 2010;163(1-3):18-23.